• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Celtic Therapeutics rebrands as Auven Therapeutics

Celtic Therapeutics rebrands as Auven Therapeutics

March 13, 2013
CenterWatch Staff

Celtic Therapeutics Management, a global private equity company focused on acquiring novel, life-saving and quality of life-enhancing products and accelerating the development of these products, has changed its name to Auven Therapeutics Management.

The name change was made to overcome confusion related to other Celtic entities, which are not part of Auven Therapeutics. The rebranding reflects its mission to provide the gold (Au) standard in drug (Ven) development, progressing promising therapeutic pharmaceutical candidates in areas of unmet medical need.

Auven Therapeutics, based in the U.S. Virgin Islands with operations in New York and Switzerland, was founded by Dr. Peter B. Corr and Stephen Evans-Freke in 2007 and is pursuing an innovative investment strategy: While structured as a private equity fund, it also operates as a drug development company.

“Capitalizing on the wealth of expertise of our development team, we take ownership and control of the development of carefully selected clinical-stage therapeutic assets in order to build value around them to the point where they are attractive acquisition opportunities for established pharmaceutical and biotechnology companies,” said  Stephen Evans-Freke, co-founder and co-managing general partner.

Auven Therapeutics has a portfolio of biologic and small molecule therapeutic candidates, primarily comprising preclinical to mid-stage development programs, for therapeutic indications including cancer, ophthalmic conditions, women’s health and orphan diseases. It owns or holds a majority interest in the therapeutic assets of ADC Therapeutics, Spirogen, Resolvyx and Kiacta, and a minority investment in Kolltan and Sprout Pharmaceuticals.

Dr. Peter B. Corr, co-founder and co-managing general partner, added, “We are excited about our portfolio of innovative therapeutic assets. In particular, our investments in Spirogen and ADC Therapeutics have great potential to develop new and much more effective treatments for a variety of cancers.”

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing